$915.67K in average volume shows that Lexeo Therapeutics Inc (LXEO) is heading in the right direction

On Tuesday, Lexeo Therapeutics Inc (NASDAQ: LXEO) opened higher 7.60% from the last session, before settling in for the closing price of $2.63. Price fluctuations for LXEO have ranged from $1.45 to $19.50 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 14.77%. Company’s average yearly earnings per share was noted 7.08% at the time writing. With a float of $25.04 million, this company’s outstanding shares have now reached $33.19 million.

Considering the fact that the conglomerate employs 72 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Lexeo Therapeutics Inc (LXEO) Insider Activity

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lexeo Therapeutics Inc is 24.57%, while institutional ownership is 87.33%. The most recent insider transaction that took place on Feb 19 ’25, was worth 19,091. In this transaction Chief Executive Officer of this company sold 4,326 shares at a rate of $4.41, taking the stock ownership to the 220,119 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Development Officer sold 1,486 for $4.41, making the entire transaction worth $6,558. This insider now owns 53,889 shares in total.

Lexeo Therapeutics Inc (LXEO) Earnings and Forecasts

According to the Wall Street analysts, stocks earnings will be around 7.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.95% during the next five years compared to -99.98% drop over the previous five years of trading.

Lexeo Therapeutics Inc (NASDAQ: LXEO) Trading Performance Indicators

Check out the current performance indicators for Lexeo Therapeutics Inc (LXEO). In the past quarter, the stock posted a quick ratio of 3.42.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.31, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -2.24 in one year’s time.

Technical Analysis of Lexeo Therapeutics Inc (LXEO)

Compared to the last year’s volume of 0.71 million, its volume of 1.23 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 4.63%. Additionally, its Average True Range was 0.57.

During the past 100 days, Lexeo Therapeutics Inc’s (LXEO) raw stochastic average was set at 22.22%, which indicates a significant increase from 9.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 176.75% in the past 14 days, which was higher than the 153.43% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $3.08, while its 200-day Moving Average is $6.86. Nevertheless, the first resistance level for the watch stands at $3.02 in the near term. At $3.21, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.45. If the price goes on to break the first support level at $2.59, it is likely to go to the next support level at $2.36. Should the price break the second support level, the third support level stands at $2.17.

Lexeo Therapeutics Inc (NASDAQ: LXEO) Key Stats

There are currently 33,197K shares outstanding in the company with a market cap of 93.95 million. Presently, the company’s annual sales total 0 K according to its annual income of -98,330 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -25,920 K.